source
- Roche's KRAS G12C inhibitor cuts death risk by 44% versus Amgen and BMS in lung cancer trialAt the European Society for Medical Oncology meeting in Madrid, Roche presented data on its next‑generation KRAS G12C inhibitor in non‑small cell lung cancer. In a head‑to‑head study against compa…
- Incyte reports strong early results for KRAS G12D inhibitor in pancreatic cancer, rivals RevMedIncyte presented phase 1 data at the European Society for Medical Oncology congress in Madrid, highlighting its KRAS G12D inhibitor INCB161734 combined with chemotherapy for pancreatic ductal adeno…Fierce Biotech · 16d agoPositive readoutPositive